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Aim: To improve the treatment results of patients with locally advanced osteosarcoma with large volume using neoadjuvant chemo-
therapy (NACT) (ifosfamide at a dose of 18 g/ml) and planning of organ-conserving surgery by evaluating the state of tumor pseudo-
capsule. Patients and Methods: A study group included 46 children aged from 7 to 18 years, mean age — 12 years. In 68% of the 
patients tumor volume was larger or significantly larger than 200 ml (from 27 to 2400 ml), mean tumor volume was 342 ml. All patients 
have been examined by X-ray radiography, CT, Doppler ultrasound. Convenient chemotherapy consisted of methotrexate at a dose 
of 12 g/ml, cisplatin (120 mg/ml) in combination with doxorubicin (75 mg/ml). If such chemotherapy was considered ineffective with 
the use of an algorithm for determination of chemotherapy efficacy, 2 cycles of chemotherapy with ifosfamide at a dose of 18 g/ml per 
course have been applied. At the stage of planning of organ-conserving surgery, the state of tumor pseudocapsule was analyzed. 
In 6 months post-operative chemotherapy was carried out with the use of methotrexate, cisplatin with doxorubicin, ifosfamide at the 
same doses. Results: Myelotoxicity of ifosfamide treatment at a dose of 18 g/ml is comparable to that of to a course of doxorubicin + 
cisplatin: the depth of leucopenia was significantly higher (p < 0.05), the duration of agranulocytosis is similar after such therapies. 
In the study group, 69.6% patients have reached grade 3–4 pathomorphosis. Organ-conserving surgery was performed in 86.9% 
of the patients. Local tumor recurrence was registered in 15.2% patients of the study group. 5-year relapse-free survival was achieved 
in 62 ± 10% (p = 0.02), the overall 5-year survival — 76.5 ± 9% (p = 0.02). Conclusions: Introduction of ifosfamide at a dose 
of 18 g/ml in the treatment scheme of pediatric patients with locally advanced osteosarcoma along with individualization of pre-oper-
ative chemotherapy, pre-operative analysis of NACT efficacy and the state of tumor pseudocapsule during planning stage of organ-
conserving surgery significantly improves efficacy of the therapy in patients with large tumor volume.
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Up to date the treatment efficacy for patients with 
locally advanced osteosarcoma with large t�mor vol�
�me �>  ��� ml� remains low compared to standard risk 
patients. For example� according to the data of Bielack 
et al. [�]� 4 year s�rvival of s�ch patients was 4�% while 
in standard risk gro�p � year s�rvival yielded 76% [�]. 
It has been shown that in the cases when t�mor vol�me 
is larger than ��� ml� microscopic metastatic t�mor 
emboli are already fo�nd in l�ngs and bone marrow [�]. 
Performance of organ�conserving s�rgery is contrain�
dicated �pon massive m�scle inj�ry [4] or significantly 
advanced soft tiss�e component ��p to 6 cm� or t�mor 
vol�me larger than ��� ml [4]. Picci et al. [�] have revealed 
a significant dependence of development of local t�mor 
rec�rrence on s�rgical p�rity of t�mor resection margins 
�pon s�rgical treatment. At the same time Li et al. [6] 
have shown that the development of local rec�rrence did 
not differ between the cases of wide margin resection 
�> � cm� and close margin resection �from � to � mm from 
t�mor edge�. T�mor pse�docaps�le is an anatomic 
str�ct�re which separates t�mor and healthy tiss�es 
[7]. Presently its pre�s�rgical determination with the �se 
of radiological methods is still problematic. By �T it is pos�
sible to determine j�st an ossification of margin zone “soft 
tiss�e�t�mor” [�]. With the �se of contrast MRT there 
co�ld be determined a margin between the t�mor and 
soft tiss�es� b�t it co�ldn’t be strictly differentiated with 
perit�moral swelling [9� ��]. Therefore� �p to date d�ring 
planning of operation the s�rgeons do not consider the 
state of pse�docaps�le [��. ��]. No p�blications abo�t 
organ conserving treatment of children with osteosar�
coma consider an importance of t�mor pse�docaps�le 
identification for s�rgical planning.
Better res�lts of osteosarcoma treatment directly 
depend on efficacy of chemotherapy and improve 
s�rvival indexes [��] and decrease the rates of local 
t�mor rec�rrence [6].
Rosen et al. [�4] have s�pposed that one of the 
methods for improvement of osteosarcoma treatment 
res�lts co�ld be the �se of new at the moment prepara�
tion ifosfamide at high doses �from �� to �� g/mІ� and 
have revealed a direct dependence between prepara�
tion dose and efficacy.
In modern literat�re there is no information on the �se 
of ifosfamide at high dose ��� g/mІ� for treatment of chil�
dren with osteosarcoma. D�ring last �� years in foreign 
and native literat�re there have been p�blished no res�lts 
abo�t individ�alization of preoperative chemotherapy 
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with the �se of radiological methods for eval�ation of its 
efficacy.
The aim of this work was an improvement of treat�
ment efficacy of children with osteosarcoma.
MATERIALS AND METHODS
In the st�dy there have been analyzed clinical records 
of 46 children from 7 to �� years old who �nderwent 
the treatment in the Department of Pediatric Oncology 
of Instit�te of Oncology �presently — National �ancer 
Instit�te� Kyiv� Ukraine� in �999����6� electronic data 
base which incl�ded USD�images� �T and MRT medical 
comments� and the res�lts of histological st�dy of me�
dicinal t�mor pathomorphism. The protocol № �6 from 
��.�9.���9 of �ommittee on Ethics of National �ancer 
Instit�te — the work does not violate ethic principles.
Age and gender distrib�tion of children is presented 
in Table �. �6 patients �7�%� were from �� to �6 years 
old. There was eq�al n�mber of girls and boys.
Table 1. Distribution of children with osteogenic sarcoma by age and gender
Patient’s age, years Gender
7–8 9–10 11–12 13–14 15–16 17–18 Male Female
Number of pa-
tients, n
2 7 11 10 15 1 23 23
Distrib�tion of the patients by t�mor localization 
is shown in Table �. In he majority of cases malignant 
t�mor was localized in femoral bone �6�.�%� or in shin 
bone ��4%�.
Table 2. Localization of tumor in children with osteogenic sarcoma
Localization of tumor in bones
TotalFemoral 
bone
Hume-
rus
Fibular 
bone
Shin 
bone
Radial 
bone
Number of pa-
tients, n
28 2 4 11 1 46
Initial t�mor vol�me was determined by �T data. 
In �� patients �6�.�%� it was larger or significantly 
larger than ��� ml. Mean t�mor vol�me was �4� ml.
In �999 we have developed a treatment protocol 
for pediatric osteosarcoma patients “UNDIOR�99”. 
It incl�ded the �se of preoperative chemotherapy 
�neoadj�vant chemotherapy — NA�T�� analysis of effi�
cacy of administered preparations� and post�operative 
chemotherapy dependent on an acq�ired medicinal 
t�mor pathomorphism. The scheme of chemotherapy 
is presented on Fig. � and �.
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Fig. 1. “UNDIOR�99” Preoperative chemotherapy. Notes: М — 
methotrexate� �� g/m²; А — dox�ribicin� 7� mg/m²; Р — cisplatin� 
��� mg/m²; Ifo — ifosfamide� �� g/m².
As it is shown on Fig. �� in all patients the therapy be�
gins from do�ble co�rse of high�dose methotrexate with 
7 days interval. Fo�rteen days later chemotherapy is con�
tin�ed with intraveno�s bol�s administration of cisplatin 
combined with doxor�bicin. At �th week of treatment 
�in � weeks after cisplatin + doxor�bicin co�rse� there 
is performed an analysis of treatment effectiveness by the 
developed algorithm for P�T efficacy determination.
Line of chemotherapy for patients with pathomorphosis 
of III–IV degree
ММ Р ММ Р ММ Р ММ Р
Line of chemotherapy for patients with pathomorphosis 
of I–II degree
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Fig. 2. “UNDIOR�99” Postoperative chemotherapy. Notes: 
М — methotrexate� �� g/m²; А — doxor�bicin� 7� mg/m²; Р — 
cisplatin� ��� mg/m²; Ifo — ifosfamide� �� g/m².
Upon establishment of efficacy of performed 
chemotherapy in each individ�al patient� chemotherapy 
regimen remains �nchanged� and the patient receives 
the second eq�al co�rse: do�ble methotrexate� 
cisplatin with doxor�bicin. In the case if performed 
therapy is considered ineffective� chemotherapy line 
is switched to do�ble co�rse of high�dose ifosfamide 
with � week interval. Upon t�mor pathomorphism of ΙΙΙ�
ΙV grades� post�operative chemotherapy has been 
performed witho�t replacement of chemoprepara�
tions� �pon t�mor pathomorphism of Ι�ΙΙ grades — with 
addition of high�dose ifosfamide �Fig. ��.
Statistical analysis of the data was done with the 
�se of comp�ter program Statistica 6.� �Statsoft Inc� 
USA�: comparison of independent variables was per�
formed by t�criterion for independent variables� analy�
sis of patient’s s�rvival — by Kaplan — Meyer c�rves.
RESULTS AND DISCUSSION
An efficacy of P�T co�rse was determined by the 
developed algorithm for determination of NA�T ef�
ficacy via analysis of patient’s t�mor state. This 
algorithm incl�des a complex of methods: clinical 
and X�ray methods� the data of �T� MRT� USVD. With 
the �se of USVD the str�ct�re and vasc�larization 
of t�mor soft tiss�e component were examined. Fig. 
� demonstrates an initial scan of patient’s t�mor and 
its scheme prior to chemotherapy. On Fig. 4 one may 
see the scan of the t�mor of the same patient and its 
scheme after performed preoperative chemotherapy. 
There has been determined a significant decrease 
of neomicrovessel n�mbers in t�mor mass and pe�
riphery� and formation of t�mor pse�docaps�le co�ld 
be observed.
Fig. 3. Scanogram of patient М. prior to chemotherapy. Ap�
proximately one h�ndred microvessels are chaotically placed 
in t�mor mass and periphery� t�mor soft tiss�e component is not 
separated from m�scles.
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Fig. 4. Scanogram of patient М. after preoperative chemotherapy. 
Single microvessels in t�mor mass and periphery are vis�alized. 
Pse�docaps�le of t�mor co�ld be seen �shown by arrow�. Posi�
tive effect of NA�T
By the data of algorithm for determination of P�T 
efficacy� effectiveness of chemotherapy co�rse 
was established only in 7 ���.�%� patients� so f�r�
ther change of chemopreparation was not req�ired. 
In � patient an eval�ation of treatment efficacy was not 
performed beca�se of p�r�lent process in the wo�nd. 
In other �� patients negative effect of performed 
chemotherapy has been registered. After therapy 
line switch� d�ring pre�operative combined examina�
tion� chemotherapy effectiveness was doc�mented 
in �6 �9�%� from �� patients and P�T efficacy in all 
7 patients treated witho�t switch of chemopreparation. 
In total� by the data of pre�operative combined exami�
nation� chemotherapy was effective in 9�.�% of the 
patients. By the data of medicinal pathomorphism� 
an expressed degree �III�IV by Havos� was registered 
only in �� patients �69.6%�. The discrepancy in de�
termination of chemotherapy efficacy with the �se 
of combined examination or medicinal pathomorphism 
is ca�sed by limited acc�racy of the developed method 
�7�.�%�. Statistical analysis of the data for the cases 
with switched chemotherapy line with the obtained 
medicinal pathomorphism� has revealed a significant 
dependence between these two variables �p < �.���. 
So� the switch of chemotherapy line significantly af�
fects medicinal pathomorphism.
Myelotoxicity of ifosfamide at the dose of �� g/mІ has 
been st�died. ΙV grade le�copenia by toxicity scale 
�T� N�I� was observed in ���% patients treated 
with high�dose ifosfamide and in ��% patients treated 
with combination of cisplatin with doxor�bicin. In other 
�7% patients treated with combination of cisplatin + 
doxor�bicin� there has been registered hematologic 
toxicity of ΙΙΙ degree by decreased le�kocyte co�nts.
There has been performed a comparison between 
maximal le�copenia and d�ration of agran�locytosis. 
Maximal le�copenia rates significantly differed after 
the co�rses of high�dose ifosfamide and cisplatin + 
doxor�bicin combination. After high�dose ifosfamide 
co�rse maximal le�copenia was more freq�ent 
�р = �.�4��� b�t d�ration of agran�locytosis in these 
patients didn’t differ significantly from that in children 
treated with cisplatin + doxor�bicin combination 
�р = �.��74�.
In the st�dy of platelet co�nts after chemotherapy 
with high�dose ifosfamide or cisplatin + doxor�bicin 
combination it has been shown that ΙV degree toxicity 
�platelet co�nts < ��·��9/l� was observed in �6 from 
�4 �67%� chemotherapy co�rses with cisplatin + 
doxor�bicin combination and only in � from �4 ��%� 
chemotherapy co�rses with high�dose ifosfamide. 
Platelet co�nts were not decreased after �� from 
�4 ��4%� chemotherapy co�rses with high�dose 
ifosfamide and after 6 from �4 ���%� co�rses with 
cisplatin + doxor�bicin.
There has been fo�nd no significant difference 
in hemoglobin levels and erythrocyte co�nts after 
chemotherapy co�rses with high�dose ifosfamide 
or combination of cisplatin with doxor�bicin.
So� after high�dose ifosfamide co�rse le�copenia 
intensity was higher compared to that after the co�rse 
of cisplatin combined with doxor�bicin �р = �.�4���� 
along with this agran�locytosis d�ration was practi�
cally similar in both therape�tic gro�ps �р = �.��74�� 
while the rate of ΙV degree thrombocytopenia was sig�
nificantly higher �by �.� fold� in the case of cisplatin + 
doxor�bicin combination than in the case of high�dose 
ifosfamide. These data evidenced on the safety of �se 
of ifosfamide at a dose of �� g/mІ and on possibility 
of its �se in clinical practice.
Pse�docaps�lifero�s t�mors were st�died 
by Doppler USD �sing an algorithm for determina�
tion of chemotherapy efficacy. It has been fo�nd that 
before operation enclosed persistent pse�docaps�le 
was present in �� patients of the main gro�p. In the 
cases when pse�docaps�le was absent in some t�mor 
region� then with the �se of USD there has been per�
formed skin mapping of problematic region with de�
termination of its depth from skin to t�mor. Sometimes 
if pse�docaps�le is placed above t�mor necrosis zone 
and is thin�walled� it co�ld be damaged with following 
effl�x of t�mor tiss�e in the wo�nd. S�ch sit�ation 
is dangero�s beca�se of possible t�mor rec�rrence.
We have performed statistical analysis of the 
state of pse�docaps�le and the risk of development 
of local t�mor rec�rrence. It has been estimated with 
significance р = �.��� that closeness of formed t�mor 
pse�docaps�le red�ces local t�mor rec�rrence after 
performed radical operative treatment. Therefore� the 
st�dy of t�mor pse�docaps�le with the �se of USVD 
prior to the s�rgery is important for planning of the 
operative treatment. We s�ppose that total absence 
of t�mor pse�docaps�le sho�ld be considered as con�
traindication for performance of organ�conserving 
operation� while its partial absence — as relative con�
traindication for performance of organ�conserving 
operation which req�ires preparatory mapping of risk 
zone and its radical removal.
Also� there has been analyzed the dependence 
between initial t�mor vol�me and the rate of local 
rec�rrence. We have performed a correlation analysis 
between variables of t�mor vol�me� the rate of rec�r�
rence or its absence. No significant correlation be�
tween these indexes was revealed �r = �.���.
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If t�mor vol�mes were distrib�ted in gro�ps 
< ��� ml or > ���; 4��; ��� ml� their correlation with 
rec�rrence cases was also insignificant �r = �.��; �.�4; 
�.�� respectively�.
So� these data allow concl�de that t�mor vol�me 
has no infl�ence on the rate of local rec�rrence. 
That’s why t�mor vol�me co�ld be considered as con�
traindication for organ�preserving operation only in the 
cases when it is impossible to cover endoprosthesis 
or transplant with soft tiss�es.
Organ�conserving operations were performed 
in �6.9% patients. Local rec�rrence was fo�nd 
in ��.�% patients. An index of � year relapse�free s�r�
vival was 6� ± ��% �р = �.���� overall s�rvival —76.� ± 
9% �р = �.���.
In concl�sion� introd�ction of ifosfamide at the 
dose of �� g/m² in the treatment scheme of pediatric 
patients with local form of osteosarcoma along with 
individ�alization of pre�operative chemotherapy� 
pre�operative analysis of NA�T efficacy and the state 
of t�mor pse�docaps�le d�ring planning stage of or�
gan�conserving operations significantly improved on�
cologic and f�nctional res�lts of the therapy of patients 
with large t�mor vol�me �p to the indexes comparable 
with standard risk gro�p.
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